Surgical Hemostats

Surgical Hemostats Market Outlook

The global surgical hemostats market is anticipated to reach approximately USD 3.5 billion by 2035, growing at a CAGR of around 6.5% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing number of surgical procedures globally, the rising prevalence of chronic diseases that necessitate surgical interventions, and the significant technological advancements in hemostatic agents. Moreover, the shift toward minimally invasive surgical techniques has further fueled the demand for effective and efficient hemostatic solutions that can ensure rapid bleeding control during operations. The ongoing research and development activities aimed at enhancing the efficacy and safety profile of hemostats are set to propel market growth in the coming decade.

Growth Factor of the Market

Several factors are driving the growth of the surgical hemostats market. The increasing volume of surgical procedures, coupled with an aging population more susceptible to ailments that require surgical intervention, significantly influences demand. Furthermore, the rise in trauma cases and emergency surgeries also contributes to the urgency for effective hemostatic agents. The growing emphasis on patient safety and the adoption of advanced technologies in surgical practices enhance the appeal of modern hemostatic products, which offer rapid and reliable bleeding control. Additionally, the growing awareness among healthcare professionals regarding new hemostatic technologies promotes wider adoption across various surgical disciplines. Regulatory approvals for novel hemostatic products further catalyze market growth, leading to improved patient outcomes and satisfaction.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 6.5% from 2025 to 2035.
• Thrombin-based hemostats are leading the product type segment in terms of revenue.
• Cardiovascular surgeries are the largest application segment, accounting for a significant share.
• North America dominates the market, driven by advanced healthcare infrastructure and high surgical volumes.
• The trend toward outpatient surgical centers is reshaping distribution channels, leading to increased availability of hemostatic products.

By Product Type

Thrombin-Based Hemostats:

Thrombin-based hemostats are widely regarded as one of the most effective solutions for promoting clotting during surgical procedures. These products utilize thrombin, a key enzyme in the coagulation cascade, to facilitate rapid hemostasis. They are particularly beneficial in surgeries where traditional methods may be inadequate or risky, such as in patients with coagulopathies. The ease of application and the immediate action of thrombin-based hemostats make them a favored choice among surgeons. They are used in various applications, including cardiovascular, orthopedic, and liver surgeries, thereby driving their market growth. Additionally, advancements in thrombin formulations and delivery mechanisms are expected to further enhance their efficacy and market penetration.

Oxidized Regenerated Cellulose-Based Hemostats:

Oxidized regenerated cellulose (ORC) hemostats are designed to promote hemostasis through a physical mechanism rather than through direct coagulation. They work by providing a scaffold that supports the body's natural clotting process. ORC hemostats are biocompatible and can be easily applied to bleeding tissues, making them ideal for a wide range of surgical applications. Their versatility allows for use in both absorbable and non-absorbable formats, catering to diverse surgical needs. As surgeons increasingly seek materials that are effective yet cause minimal tissue trauma, ORC hemostats are gaining popularity. The growing demand for innovative hemostatic agents in minimally invasive surgeries further bolsters this segment of the market.

Gelatin-Based Hemostats:

Gelatin-based hemostats are popular for their biocompatibility and biodegradability, making them an ideal choice for a variety of surgical applications. These agents act by providing a gelatinous matrix that aids in the natural clotting process. Their ability to absorb blood and promote coagulation makes them particularly valuable in sites where traditional methods cannot be easily applied. Gelatin-based hemostats are commonly used in general and orthopedic surgeries, contributing significantly to their market share. The increasing number of surgical procedures and the growing adoption of minimally invasive techniques are expected to drive the demand for gelatin-based hemostats, providing opportunities for innovation in this product type.

Collagen-Based Hemostats:

Collagen-based hemostats leverage the natural properties of collagen to promote hemostasis and tissue healing. They are particularly useful in scenarios wherein traditional sutures may not be practical or effective. The molecular structure of collagen supports cellular growth and regeneration, thereby facilitating a quicker recovery process for patients. Collagen hemostats are highly biocompatible, minimizing the risk of adverse reactions and enhancing patient safety during and after surgical interventions. This product type is gaining traction in various surgical specialties, including neurosurgery and orthopedics, as medical professionals increasingly recognize its benefits in promoting effective wound healing. The market for collagen-based hemostats is expected to expand as surgeons prioritize patient outcomes.

Combination Hemostats:

Combination hemostats represent an innovative approach to managing bleeding during surgical procedures by incorporating multiple hemostatic agents into a single product. This versatility allows for enhanced efficacy in promoting coagulation and can be tailored to meet specific surgical needs. By combining different mechanisms, such as the physical scaffolding of cellulose with the biochemical action of thrombin or gelatin, combination hemostats can provide synergistic benefits that traditional hemostats may lack. Physicians are increasingly adopting these advanced solutions, recognizing their potential to improve surgical outcomes and minimize blood loss. As the demand for tailored surgical solutions grows, the combination hemostat segment is poised for significant growth in the coming years.

By Application

Cardiovascular Surgery:

Cardiovascular surgery applications dominate the surgical hemostats market due to the high incidence of procedures such as coronary artery bypass grafting and valve replacements. In these surgeries, effective hemostasis is critical to minimize blood loss and ensure optimal patient outcomes. The complexity of cardiovascular procedures demands the use of advanced hemostatic agents that can provide rapid and reliable bleeding control. Thrombin-based hemostats, in particular, are widely used in this field due to their effectiveness in promoting clot formation. Moreover, the growing incidence of cardiovascular diseases further drives the demand for surgical hemostats, fostering innovations that enhance performance and safety in these high-stakes environments.

General Surgery:

The general surgery segment is also a significant contributor to the surgical hemostats market, encompassing a wide range of procedures that require hemostatic solutions. General surgeries, including appendectomies, cholecystectomies, and hernia repairs, demand effective bleeding control to minimize complications. The use of hemostatic agents like gelatin and oxidized regenerated cellulose is prevalent in this area, as these products can easily be applied and provide efficient hemostatic capabilities. The increase in elective surgeries and an aging population further propel the growth of this segment. As surgical techniques continue to advance, the need for innovative hemostatic solutions that enhance surgical efficiency and patient recovery is becoming increasingly important.

Orthopedic Surgery:

Orthopedic surgery requires precise bleeding control due to the intricate nature of musculoskeletal procedures. The surgical hemostats market in this segment is witnessing substantial growth, driven by rising incidences of trauma cases and degenerative diseases such as osteoarthritis. Hemostatic agents, especially those that are easy to apply and provide rapid clotting capabilities, are essential in orthopedic surgeries, including joint replacements, fracture repairs, and spinal surgeries. The growing trend toward minimally invasive orthopedic procedures further emphasizes the need for effective hemostatic solutions that can facilitate quicker recovery times and minimize complications. This segment presents a promising opportunity for manufacturers to innovate and deliver advanced hemostatic products tailored to orthopedic needs.

Neurosurgery:

Neurosurgery is a highly sensitive area where meticulous hemostatic control is vital due to the proximity of surgical sites to critical structures. The surgical hemostats market within this specialty is marked by the demand for products that minimize blood loss while ensuring safety and efficacy. Thrombin-based and collagen-based hemostats are frequently utilized in neurosurgical procedures to control bleeding effectively and promote tissue healing. The increasing prevalence of neurological disorders requiring surgical interventions, combined with advances in surgical techniques, continues to drive the growth of hemostatic products specific to neurosurgery. As research progresses, the development of specialized hemostatic agents that cater to the unique challenges of neurosurgery will further bolster this market segment.

Others:

The "Others" application segment encompasses a range of surgical specialties, including gynecological surgery, urological surgery, and plastic surgery, among others. Each of these specialties presents unique challenges regarding bleeding control, leading to a diversified demand for surgical hemostats. In gynecological surgeries, for instance, the need for effective hemostasis to prevent excessive blood loss during procedures such as hysterectomies has led to increased utilization of hemostatic agents. Similarly, in plastic surgery, where aesthetics are paramount, the use of hemostats that support healing with minimal scarring is gaining traction. The versatility of various hemostatic agents to cater to different surgical needs underlines the potential growth of this segment as healthcare continues to evolve.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for surgical hemostats, accounting for a significant share of the market due to their extensive surgical operations. Major surgical procedures performed within hospitals require immediate access to effective hemostatic agents to manage bleeding effectively. The availability of a diverse range of hemostatic products within hospitals enables surgeons to choose the best option tailored to specific surgical scenarios. Additionally, hospitals often have established relationships with manufacturers and suppliers, fostering continuous supply and product availability. The increasing number of surgical procedures performed in hospitals, coupled with advancements in surgical techniques, is expected to drive the demand for hemostatic products through this channel. Moreover, hospital procurement practices are increasingly focused on ensuring patient safety, leading to the adoption of innovative hemostatic solutions.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) represent a growing distribution channel for surgical hemostats due to the rising trend of outpatient surgical procedures. These centers are equipped to perform various surgeries that do not require overnight hospitalization, making effective bleeding control essential for successful outcomes. The convenience and efficiency of ASCs foster increased patient throughput, which in turn escalates the demand for hemostatic agents. As patients increasingly prefer less invasive surgical options, the ASC market is expected to grow, prompting manufacturers to develop targeted hemostatic products that cater to this channel. The competitive pricing and accessibility of surgical hemostats in ASCs are crucial factors that contribute to their market growth.

Specialty Clinics:

Specialty clinics also play a significant role as a distribution channel for surgical hemostats, particularly in fields such as dermatology, orthopedics, and gastroenterology. These clinics often perform procedures that require efficient bleeding control but fall outside traditional hospital settings. The demand for hemostatic agents in specialty clinics is driven by the increasing number of minimally invasive procedures being conducted in these environments. As healthcare shifts toward more outpatient care, specialty clinics are expected to adopt and stock a variety of hemostatic products to meet their surgical needs. Furthermore, the personalized nature of care in specialty clinics allows for tailored product selection, enhancing the effectiveness of hemostatic solutions used in specific procedures.

Online Sales:

The online sales channel for surgical hemostats is gaining traction due to the convenience and accessibility it offers to healthcare providers. With the rapid digitization of healthcare, many hospitals and clinics are turning to e-commerce platforms for procuring medical supplies, including hemostatic agents. Online sales provide a streamlined ordering process, enabling healthcare professionals to easily access a variety of hemostatic products from multiple suppliers. Moreover, the ability to compare prices and product features online enhances informed purchasing decisions. As the demand for surgical hemostats continues to rise, the online sales channel is expected to grow, driven by technological advancements and changing purchasing behaviors among healthcare providers.

By Ingredient Type

Plant-Based Hemostats:

Plant-based hemostats represent an innovative segment of the surgical hemostats market, utilizing natural components derived from plants to promote coagulation. These products are increasingly favored due to their biocompatibility and lower risk of adverse reactions compared to synthetic alternatives. Plant-derived agents can effectively manage bleeding in various surgical applications, supporting sustainable practices in healthcare. The rising trend toward eco-friendly and natural products is driving the demand for plant-based hemostats, appealing to both healthcare professionals and patients alike. As research continues to unveil the potential of various plant extracts in hemostatic applications, this segment is expected to witness significant growth.

Animal-Based Hemostats:

Animal-based hemostats, particularly those derived from collagen and gelatin, have been long established in the market for their effectiveness in promoting hemostasis. These agents leverage natural biological processes, making them an attractive option for surgeons seeking reliable solutions. The market for animal-based hemostats is driven by their versatility and wide application across various surgical fields, including orthopedics, general surgery, and more. Furthermore, as surgical procedures increasingly prioritize patient safety, the demand for biocompatible hemostatic agents is expected to rise. The ongoing research into optimizing the formulations and safety profiles of animal-based hemostats will likely enhance their adoption across different surgical settings.

Synthetic Hemostats:

Synthetic hemostats are rapidly gaining popularity in the surgical hemostats market due to their advanced properties and customizable formulations. These products are engineered to provide tailored solutions for specific surgical challenges, offering reliable bleeding control without the limitations associated with biological alternatives. Synthetic hemostats are often designed to be highly effective in various surgical environments, appealing to healthcare professionals who prioritize innovation and performance. As healthcare continues to evolve with the introduction of new technologies, the demand for synthetic hemostats is expected to grow, particularly in specialized surgical fields where precision and efficacy are paramount. This segment presents a significant opportunity for manufacturers focusing on R&D and product differentiation.

Others:

The "Others" ingredient type category includes a variety of hemostatic products that do not fall into the primary classifications of plant-based, animal-based, or synthetic types. This segment may include novel formulations or composite products designed to enhance hemostatic efficacy through unique mechanisms. As the surgical hemostats market continues to innovate, the "Others" category is likely to see growth driven by technological advancements and the development of new materials. Healthcare professionals seeking alternatives to traditional hemostatic agents may turn to these novel products, which could offer improved safety profiles and effectiveness in diverse surgical applications. The ongoing exploration of alternative ingredients and formulations is expected to contribute to this segment's expansion.

By Region

The North American region holds a dominant position in the surgical hemostats market, accounting for nearly 40% of the total market share. This can be attributed to the presence of advanced healthcare infrastructure, a high volume of surgical procedures, and significant investments in medical research and development. The United States, in particular, leads in surgical innovations and the adoption of cutting-edge hemostatic technologies, fostering a competitive environment for key market players. With a projected CAGR of 6.8%, the North American surgical hemostats market continues to expand, driven by the increasing prevalence of chronic diseases and the growing demand for minimally invasive surgeries.

Europe follows closely as the second-largest market, driven by similar healthcare advancements and a rising elderly population. The European surgical hemostats market is anticipated to grow at a CAGR of around 6.3% during the forecast period as healthcare systems increasingly prioritize patient safety and effective bleeding control. Additionally, countries such as Germany, France, and the UK are investing in research and innovation to improve surgical outcomes, thereby contributing to market growth. Meanwhile, the Asia Pacific region is expected to witness the highest growth rate of around 7.5%, driven by increasing surgical procedures, improving healthcare infrastructure, and rising awareness regarding advanced hemostatic solutions.

Opportunities

As the surgical hemostats market continues to evolve, it presents several opportunities for growth and innovation. One notable opportunity lies in the development of biodegradable hemostatic agents that not only provide effective bleeding control but also minimize environmental impact. With the rising emphasis on sustainability in healthcare practices, manufacturers that innovate in this area can gain a competitive edge. The trend toward personalized medicine is also creating opportunities for tailored hemostatic solutions that address specific patient needs and surgical challenges. By focusing on R&D to create specialized products, companies can cater to niche markets and enhance their positioning within the industry.

Moreover, the increasing prevalence of chronic diseases and the growing geriatric population are driving demand for surgical interventions, leading to an upswing in the need for reliable hemostatic agents. Emerging markets in Asia Pacific and Latin America present significant growth opportunities, as healthcare systems continue to expand and adopt modern surgical practices. The rise of outpatient surgeries and ambulatory surgical centers is reshaping the landscape for hemostatic products, prompting manufacturers to create user-friendly and effective solutions that cater to this channel. By capitalizing on these trends, companies can position themselves for sustained growth in the surgical hemostats market.

Threats

While the surgical hemostats market presents numerous opportunities, it is not without its threats. One significant threat stems from regulatory challenges and stringent guidelines surrounding the approval of new hemostatic products. Navigating the complex regulatory landscape can pose hurdles for manufacturers looking to introduce innovative solutions to the market. Compliance with varying regulations across different countries can lead to delays in product launches or increased costs, thereby affecting profitability and market position. Additionally, the competitive nature of the market means that companies must continuously innovate and improve their product offerings to remain relevant, which can strain resources and impact financial performance.

Another major threat to the surgical hemostats market is the increasing prevalence of counterfeit and substandard products. The presence of low-quality alternatives can undermine consumer trust, leading to reduced demand for legitimate hemostatic agents. Furthermore, the global supply chain disruptions experienced during the COVID-19 pandemic have highlighted vulnerabilities in sourcing and distribution, potentially impacting product availability and pricing. Companies must remain vigilant in ensuring product authenticity and quality, as failure to do so may not only damage brand reputation but also pose risks to patient safety.

Competitor Outlook

• Johnson & Johnson
• Medtronic
• Baxter International Inc.
• Ethicon, Inc.
• CSL Behring
• BD (Becton, Dickinson and Company)
• Hemostasis, Inc.
• Terumo Corporation
• Stryker Corporation
• Z-Medica, LLC
• Integra LifeSciences Holdings Corporation
• Cohera Medical, Inc.
• Surgeon’s Choice
• GELITA AG
• Sanofi

The competitive landscape of the surgical hemostats market is characterized by a mix of established players and emerging companies focused on innovation and differentiation. Major companies such as Johnson & Johnson, Baxter International, and Medtronic leverage their extensive product portfolios and strong market presence to dominate the industry. These companies invest heavily in research and development to introduce advanced hemostatic solutions that cater to evolving surgical needs. Additionally, strategic partnerships and collaborations with healthcare providers enhance their capabilities to deliver tailored solutions, thus strengthening their market position.

Emerging players in the surgical hemostats market are focusing on niche segments and innovative product offerings, providing competition to established brands. For instance, Z-Medica specializes in innovative hemostatic agents that cater to the military and emergency medicine sectors. By concentrating on specific applications and leveraging unique technologies, these companies can carve out significant market share. Furthermore, companies like Cohera Medical are exploring the development of novel biodegradable hemostatic agents, which aligns with the growing demand for sustainable healthcare solutions.

Given the dynamic nature of the surgical hemostats market, companies must remain agile and responsive to changing market demands. Continuous market research, investment in technology, and a focus on customer feedback are essential in maintaining competitiveness. As the industry evolves, collaboration with healthcare professionals and institutions will also play a crucial role in driving product adoption and fostering innovation. Ultimately, the competitive landscape is poised for further transformation, with both established and emerging players vying for market leadership.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Sanofi
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 GELITA AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 CSL Behring
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Ethicon, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Z-Medica, LLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hemostasis, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Terumo Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Stryker Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Cohera Medical, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Baxter International Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Surgeon’s Choice
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Integra LifeSciences Holdings Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Surgical Hemostats Market, By Application
    • 6.1.1 Cardiovascular Surgery
    • 6.1.2 General Surgery
    • 6.1.3 Orthopedic Surgery
    • 6.1.4 Neurosurgery
    • 6.1.5 Others
  • 6.2 Surgical Hemostats Market, By Product Type
    • 6.2.1 Thrombin-Based Hemostats
    • 6.2.2 Oxidized Regenerated Cellulose-Based Hemostats
    • 6.2.3 Gelatin-Based Hemostats
    • 6.2.4 Collagen-Based Hemostats
    • 6.2.5 Combination Hemostats
  • 6.3 Surgical Hemostats Market, By Ingredient Type
    • 6.3.1 Plant-Based Hemostats
    • 6.3.2 Animal-Based Hemostats
    • 6.3.3 Synthetic Hemostats
    • 6.3.4 Others
  • 6.4 Surgical Hemostats Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Surgical Hemostats Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Surgical Hemostats market is categorized based on

By Product Type

• Thrombin-Based Hemostats
• Oxidized Regenerated Cellulose-Based Hemostats
• Gelatin-Based Hemostats
• Collagen-Based Hemostats
• Combination Hemostats

By Application

• Cardiovascular Surgery
• General Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales

By Ingredient Type

• Plant-Based Hemostats
• Animal-Based Hemostats
• Synthetic Hemostats
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Medtronic
• Baxter International Inc.
• Ethicon, Inc.
• CSL Behring
• BD (Becton, Dickinson and Company)
• Hemostasis, Inc.
• Terumo Corporation
• Stryker Corporation
• Z-Medica, LLC
• Integra LifeSciences Holdings Corporation
• Cohera Medical, Inc.
• Surgeon’s Choice
• GELITA AG
• Sanofi